- Home
- BWIV vs KZIA Comparison
BWIV vs KZIA Comparison
Compare BWIV & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BWIV | KZIA |
|---|---|---|
| Founded | 2025 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 176.0M | 186.7M |
| IPO Year | 2025 | 2002 |
Fundamental Metrics
Financial Performance| Metric | BWIV | KZIA |
|---|---|---|
| Price | $9.99 | $9.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $28.36 |
| AVG Volume (30 Days) | 43.1K | ★ 277.0K |
| Earning Date | N/A | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.89 | $4.86 |
| 52 Week High | $10.00 | $17.40 |
Technical Indicators
Market Signals| Indicator | BWIV | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 55.85 | 34.77 |
| Support Level | $9.90 | $9.01 |
| Resistance Level | $10.00 | $14.85 |
| Average True Range (ATR) | 0.01 | 0.65 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 85.71 | 12.48 |
Price Performance
Historical ComparisonAbout BWIV Blue Water Acquisition Corp. IV Class A Ordinary Shares
Blue Water Acquisition Corp IV is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.